# US 2026/0078356 A1 · Compositions and methods for treating ornithine transcarbamylase deficiency

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0078356 A1
- Document ID: US20260078356A1
- Status: Published application
- Kind: A1
- Application number: 19/279,738
- Filed: 2025-07-24
- Published: 2026-03-19
- Earliest claimed: 2018-12-06
- Assignees: Arcturus Therapeutics, Inc.
- Applicants: Arcturus Therapeutics, Inc.
- Inventors: Carlos G. PEREZ-GARCIA; Kiyoshi TACHIKAWA; Daiki MATSUDA; Padmanabh CHIVUKULA
- Web page: https://patentgrep.com/patent/US20260078356A1

## CPC

- C12N 9/1018: {Carboxy- and carbamoyl transferases (2.1.3)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C12Y 201/03003: Ornithine carbamoyltransferase (2.1.3.3)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides a modified human OTC protein having improved properties for the treatment of OTC deficiency in a patient. Preferably, the protein of the disclosure is produced from a codon optimized mRNA suitable for administration to a patient suffering from OTC deficiency wherein upon administration of the mRNA to the patient, the protein of the disclosure is expressed in the patient in therapeutically effective amounts to treat OTC deficiency. The present disclosure also provides codon optimized mRNA sequences encoding wild type human OTC comprising a 5′ UTR derived from a gene expressed by Arabidopsis thaliana for use in treating OTC deficiency in a patient.

## Claims

### Claim 1

An ornithine transcarbamylase (OTC) protein comprising the amino acid sequence of SEQ ID NO:4 and having OTC enzymatic activity.

### Claim 2 (depends on 1)

A polynucleotide encoding the OTC protein of claim 1.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 2)

The polynucleotide of claim 2, wherein the polynucleotide is an mRNA or DNA.

### Claim 6 (depends on 5)

The polynucleotide of claim 5, wherein the polynucleotide is an mRNA comprising a 3′poly A tail.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 5)

The polynucleotide of claim 5, wherein the polynucleotide is an mRNA comprising a 5′ untranslated region (5′UTR).

### Claim 10 (depends on 9)

The polynucleotide of claim 9, wherein the 5′UTR comprises a sequence of a 5′ UTR of human IL-6, alanine aminotransferase 1, human apolipoprotein E, human fibrinogen alpha chain, human transthyretin, human haptoglobin, human alpha-1-antichymotrypsin, human antithrombin, human alpha-1-antitrypsin, human albumin, human beta globin, human complement C3, human complement C5, SynK (thylakoid potassium channel protein derived from the cyanobacteria, Synechocystis sp.), mouse beta globin, mouse albumin, or tobacco etch virus, or a sequence of a 5′ UTR of a gene expressed by Arabidopsis thaliana.

### Claim 11 (depends on 10)

The polynucleotide of claim 10, wherein the 5′ UTR comprises a sequence selected from SEQ ID NO: 6, SEQ ID NOS: 125-127 or SEQ ID NOS: 230-250.

### Claim 12 (depends on 10)

The polynucleotide of claim 10, wherein the 5′UTR comprises a sequence of a 5′ UTR of mouse beta globin.

### Claim 13 (depends on 5)

The polynucleotide of claim 5, wherein the polynucleotide is an mRNA comprising a 3′ UTR.

### Claim 14 (depends on 13)

The polynucleotide of claim 13, wherein the 3′ UTR comprises a sequence selected from SEQ ID NOS: 16-22.

### Claim 15 (depends on 5)

The polynucleotide of claim 5, wherein the polynucleotide is an mRNA comprising a Kozak sequence of SEQ ID NO: 23 or a partial Kozak sequence of SEQ ID NO: 24.

### Claim 16 (depends on 5)

The polynucleotide of claim 5, wherein the polynucleotide is an mRNA comprising a 5′ cap.

### Claim 17

(canceled)

### Claim 18 (depends on 5)

The polynucleotide of claim 5, wherein
(a) the polynucleotide is an mRNA comprising an optimized coding region comprising the sequence of SEQ ID NO: 221, wherein T is substituted with U; or
(b) the polynucleotide is DNA comprising an optimized coding region comprising the sequence of SEQ ID NO: 221.

### Claim 19 (depends on 5)

The polynucleotide of claim 5, wherein the polynucleotide is an mRNA comprising the sequence of SEQ ID NO: 119, SEQ ID NO: 251, or SEQ ID NO: 252.

### Claim 20 (depends on 5)

The polynucleotide of claim 5, wherein the polynucleotide is an mRNA and wherein
(a) the percentage of uracil nucleobases in the coding region of the polynucleotide is reduced with respect to the percentage of uracil nucleobases in the wild-type OTC nucleic acid sequence; or
(b) 1-100% of the uridines are modified uridine analogs; or
(c) 1-100% of the uridine nucleotides are each independently a modified uridine analog selected from the group consisting of 5-methoxyuridine, N1-methylpseudouridine, 5-hydroxyuridine, 5-methyluridine, 5-hydroxymethyluridine, 5-carboxyuridine, 5-carboxymethylesteruridine, 5-formyluridine, 5-propynyluridine, 5-bromouridine, 5-fluorouridine, 5-iodouridine, 2-thiouridine, 6-methyluridine, N1-ethylpseudouridine, N1-propylpseudouridine, N1-cyclopropylpseudouridine, N1-phenylpseudouridine, N1-aminomethylpseudouridine, N3-methylpseudouridine, N1-hydroxypseudouridine, N1-hydroxymethylpseudouridine, 5-methoxycarbonylmethyl-2-thiouridine, 5-methylaminomethyl-2-thiouridine, 5-carbamoylmethyluridine, 5-carbamoylmethyl-2′-O-methyluridine, 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine, 5-methylaminomethyl-2-selenouridine, 5-carboxymethyluridine, 5-methyldihydrouridine, 5-taurinomethyluridine, 5-taurinomethyl-2-thiouridine, 5-(isopentenylaminomethyl)uridine, 2′-O-methylpseudouridine, 2-thio-2′O-methyluridine, and 3,2′-O-dimethyluridine; or
(d) 100% of the uridine nucleotides are 5-methoxyuridine; or
(e) 100% of the uridine nucleotides are N1-methylpseudouridine.

### Claim at position 21

-27. (canceled)

### Claim 28 (depends on 2)

A pharmaceutical composition comprising the polynucleotide of claim 2 and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carried is a lipid formulation.

### Claim 29 (depends on 20)

A pharmaceutical composition comprising the polynucleotide of claim 20 and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carried is a lipid formulation.

### Claim at position 24

-35. (canceled)

### Claim 36 (depends on 28)

A method of treating OTC deficiency in a patient identified as suffering from OTC deficiency, comprising administering to the patient, a pharmaceutical composition of claim 28, wherein upon administration of the pharmaceutical composition to the patient, the OTC protein is expressed in the patient.

### Claim 37 (depends on 5)

A method of treating OTC deficiency in a patient identified as suffering from OTC deficiency, comprising administering to the patient a polynucleotide of claim 5, wherein the polynucleotide is an mRNA and expresses the OTC protein in the patient.

### Claim 38 (depends on 5)

A vector comprising the polynucleotide of claim 5.

### Claim at position 28

-76. (canceled)
